PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  10:45 2022-08-12 am EDT
49.34 USD   +2.16%
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:52aOncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
AQ
08:49aThere are two ways to see inflation data
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER INC : Berenberg sticks Neutral

05/27/2022 | 08:18am EDT

In a research note published by Luisa Hector, Berenberg gives a Neutral rating to the stock. The target price is still set at USD 50.


© MarketScreener with dpa-AFX Analyser 2022
All news about PFIZER, INC.
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:52aOncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational..
AQ
08:49aThere are two ways to see inflation data
MS
07:33aPfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
06:46aPfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
02:33aGSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
01:15aHaleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
12:20aHaleon Says it Hasn't Been Notified About Litigation on Zantac Drug
DJ
08/11US Stocks Close Mixed Thursday Following Surprise Producer Price Drop
MT
08/11US Stocks Close Mixed Thursday Following Surprise Producer Price Drop
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,57x
Yield 2022 3,35%
Capitalization 271 B 271 B -
EV / Sales 2022 2,55x
EV / Sales 2023 3,23x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 48,29 $
Average target price 56,53 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-18.22%271 020
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
ABBVIE INC.4.93%251 211
NOVO NORDISK A/S7.63%248 905